Biotech · Private company · Madison, WI, US
FluGen Inc
Track this companyFree. Adds FluGen Inc to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- Cam2020 M2SR H3N2 influenza vaccinePhase 1 · Influenza VaccineClinicalTrials.gov · fetched Nov 12, 2026
- Fluzone HD IIVPhase 1 · Influenza VaccineClinicalTrials.gov · fetched Nov 12, 2026
- HD Sing2016 M2SR H3N2 influenza vaccinePhase 1 · Influenza AClinicalTrials.gov · fetched Nov 12, 2026
- LD Bris10 M2SR H3N2 influenza vaccinePhase 1 · Influenza AClinicalTrials.gov · fetched Nov 12, 2026
- LD Sing2016 M2SR H3N2 influenza vaccinePhase 1 · Influenza AClinicalTrials.gov · fetched Nov 12, 2026
- MD Sing2016 M2SR H3N2 influenza vaccinePhase 1 · Influenza AClinicalTrials.gov · fetched Nov 12, 2026
- Sing2016 M2SR H3N2 influenza vaccinePhase 1 · Influenza VaccineClinicalTrials.gov · fetched Nov 12, 2026
- the H3N2 M2SR monovalent influenza vaccinePhase 1 · FluClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older AdultsPHASE1 · COMPLETED · started Jun 14, 2022ClinicalTrials.gov NCT05163847 · fetched Nov 12, 2026
- Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years OldPHASE1 · COMPLETED · started Jun 30, 2021ClinicalTrials.gov NCT04785794 · fetched Nov 12, 2026
- Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza VaccinesPHASE1 · COMPLETED · started Sep 3, 2019ClinicalTrials.gov NCT03999554 · fetched Nov 12, 2026
- Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy VolunteersPHASE1 · COMPLETED · started Jun 1, 2016ClinicalTrials.gov NCT02822105 · fetched Nov 12, 2026
NIH awards2
- IND-enabling studies of an intranasal, single-replication M2SR influenza vaccineFiscal year 2025 · $349.6KNIH RePORTER 5SB1AI120269-06 · fetched Nov 12, 2026
- IND-enabling studies of an intranasal, single-replication M2SR influenza vaccineFiscal year 2024 · $349.6KNIH RePORTER 5SB1AI120269-05 · fetched Nov 12, 2026